The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion, recommending the granting of a marketing authorisation for Revolade® (eltrombopag olamine), for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.